BioSyent Inc. (CVE:RX) Insider Sells C$2,566,496.00 in Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 230,800 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total value of C$2,566,496.00.

BioSyent Stock Down 0.1 %

BioSyent stock opened at C$11.51 on Thursday. The firm has a market capitalization of C$133.40 million, a P/E ratio of 19.20 and a beta of 0.93. The company has a 50-day simple moving average of C$11.08 and a 200-day simple moving average of C$10.32. BioSyent Inc. has a one year low of C$8.24 and a one year high of C$11.74. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13.

BioSyent (CVE:RX) last announced its quarterly earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, meeting the consensus estimate of C$0.13. The company had revenue of C$8.95 million for the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. As a group, equities analysts expect that BioSyent Inc. will post 0.6944444 earnings per share for the current year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.